X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ALKEM LABORATORIES - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ALKEM LABORATORIES DISHMAN PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 25.1 - - View Chart
P/BV x 3.3 7.6 43.8% View Chart
Dividend Yield % 0.7 0.6 117.2%  

Financials

 DISHMAN PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ALKEM LABORATORIES
Mar-16
DISHMAN PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3741,589 23.6%   
Low Rs1291,232 10.5%   
Sales per share (Unadj.) Rs197.8417.5 47.4%  
Earnings per share (Unadj.) Rs21.256.3 37.7%  
Cash flow per share (Unadj.) Rs34.764.7 53.7%  
Dividends per share (Unadj.) Rs2.0012.70 15.7%  
Dividend yield (eoy) %0.80.9 88.3%  
Book value per share (Unadj.) Rs179.9292.9 61.4%  
Shares outstanding (eoy) m80.69119.57 67.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.4 37.7%   
Avg P/E ratio x11.925.1 47.4%  
P/CF ratio (eoy) x7.221.8 33.2%  
Price / Book Value ratio x1.44.8 29.1%  
Dividend payout %9.422.6 41.8%   
Avg Mkt Cap Rs m20,306168,653 12.0%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3559,171 58.4%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96149,915 32.0%  
Other income Rs m2651,645 16.1%   
Total revenues Rs m16,22651,561 31.5%   
Gross profit Rs m4,1038,482 48.4%  
Depreciation Rs m1,0911,006 108.4%   
Interest Rs m944671 140.8%   
Profit before tax Rs m2,3348,451 27.6%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,606 38.8%   
Profit after tax Rs m1,7116,731 25.4%  
Gross profit margin %25.717.0 151.3%  
Effective tax rate %26.719.0 140.6%   
Net profit margin %10.713.5 79.5%  
BALANCE SHEET DATA
Current assets Rs m11,01827,062 40.7%   
Current liabilities Rs m9,51715,324 62.1%   
Net working cap to sales %9.423.5 40.0%  
Current ratio x1.21.8 65.6%  
Inventory Days Days11067 166.1%  
Debtors Days Days3541 84.4%  
Net fixed assets Rs m16,30412,610 129.3%   
Share capital Rs m161239 67.5%   
"Free" reserves Rs m12,90734,490 37.4%   
Net worth Rs m14,51635,027 41.4%   
Long term debt Rs m4,1891,212 345.8%   
Total assets Rs m29,80554,387 54.8%  
Interest coverage x3.513.6 25.5%   
Debt to equity ratio x0.30 834.4%  
Sales to assets ratio x0.50.9 58.3%   
Return on assets %8.913.6 65.5%  
Return on equity %11.819.2 61.3%  
Return on capital %17.524.9 70.5%  
Exports to sales %24.812.9 191.5%   
Imports to sales %3.73.1 121.1%   
Exports (fob) Rs m3,9566,461 61.2%   
Imports (cif) Rs m5961,540 38.7%   
Fx inflow Rs m4,9526,563 75.4%   
Fx outflow Rs m6973,012 23.1%   
Net fx Rs m4,2553,552 119.8%   
CASH FLOW
From Operations Rs m2,7867,259 38.4%  
From Investments Rs m-1,5291,864 -82.0%  
From Financial Activity Rs m-941-9,273 10.1%  
Net Cashflow Rs m316-150 -210.9%  

Share Holding

Indian Promoters % 61.4 66.9 91.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 33.1 11.2%  
FIIs % 12.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 0.0 -  
Shareholders   46,261 68,381 67.7%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS